You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 122 No. 12, December 1987 TABLE OF CONTENTS
  Archives
  •  Online Features
  PAPERS READ BEFORE THE ANNUAL MEETING OF THE SOCIETY OF SURGICAL ONCOLOGY, LONDON, APRIL 27 TO APRIL 30, 1987-PART II
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on Web of Science (4)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Immunotherapy of Pulmonary Metastases Using Monoclonal Antibody to T-Cell Suppressor Factor and Interleukin 2

Benjamin Kim, MD; Patricia Warnaka; Michael Iverson, PhD; Anthony L. Imbembo, MD

Arch Surg. 1987;122(12):1455-1459.


Abstract

• Tumor-induced immune suppression of the host may pose a barrier to successful immunotherapy. A monoclonal antibody (MAb 14-12) able to bind and inhibit murine soluble T-cell suppressor factor was tested for in vivo antitumor activity by treatment of mice bearing three-day established pulmonary metastases of a weakly immunogenic methylcholanthreneinduced fibrosarcoma (MCA 106). Administration intraperitoneally in combination with interleukin 2 (IL-2), a growth factor for activated T lymphocytes, resulted in a significant reduction (60% to 90%) of metastases. Neither IL-2 nor monoclonal antibody alone had significant antitumor effects. This study demonstrates in vivo potentiation of IL-2 antitumor activity with an anti—T-cell suppressor factor and points to possible strategies for clinical application.

(Arch Surg 1987;122:1455-1459)



Author Affiliations

From the Department of Surgery, Cleveland Metropolitan General Hospital and Case Western Reserve University School of Medicine, Cleveland (Drs Kim and Imbembo and Ms Warnaka); and the Medical Biology Institute, La Jolla, Calif (Dr Iverson).


Footnotes

Accepted for publication July 16, 1987.

Read before the Annual Meeting of the Society of Surgical Oncology, London, April 30, 1987.

Reprint requests to Department of Surgery, Cleveland Metropolitan General Hospital, 3395 Scranton Rd, Cleveland, OH 44109 (Dr Kim).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1987 American Medical Association. All Rights Reserved.